Prelude Therapeutics Inc. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Altay Therapeutics Inc. has divulged signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, diabetes, inflammatory disorders, muscular dystrophy, neurodegeneration and thyroid disorders.
Transition Bio Ltd. has disclosed YTH domain-containing protein 1 (YTHDC1; YT521-B) inhibitors reported to be useful for the treatment of acute myeloid leukemia (AML).
Despite the variety of treatments available for acute myeloid leukemia (AML), their therapeutic efficacy remains limited, and the 5-year survival rate is still below 30%. Epigenetic changes, including DNA methylation and histone modification, appear to play a role in AML development and progression, emerging as promising targets.
Head and neck cancer is the sixth most common cancer worldwide, and oral squamous cell carcinoma (OSCC) accounts for about 2% of all cancers and 1.9% of cancer-related deaths globally. OSCC is characterized by local invasiveness and lymph node metastatic ability, making it a very malignant cancer.
Glioblastoma is the most common and aggressive malignant brain tumor in adults. Although microtubule-targeting agents (MTAs) are among the most widely used first-line therapies in cancer, their efficacy in glioblastoma is limited by poor penetration of the blood–brain barrier.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits observed with next-generation targeted therapies in ALK- and ROS1-rearranged NSCLC. Given the molecular heterogeneity of EGFR-mutant NSCLC, which includes over 100 distinct mutations, there is a continued need for more effective and mutation-specific therapeutic strategies.
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated non-small-cell lung cancer. The partnership in the expanding ADC space began nearly two years ago in a $22 billion deal.
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as Protagonist Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. led the charge with positive results for its potential blockbuster rusfertide in treating a rare leukemia.
RSS
